Transthyretin (ATTR) amyloidosis is a rare, progressive, and multisystem disease, today recognized as underdiagnosed and characterized by significant diagnostic delays, which compromise timely access to effective disease-modifying therapies. In light of recent therapeutic innovations, early diagnosis and integrated management are key to improving clinical outcomes and patients' quality of life. The AMY-Way project was created to identify operational strategies to enhance the diagnostic and care pathways for ATTR amyloidosis in Italy through a multidisciplinary approach. A group of experts, using the mini-Delphi methodology, developed six priority thematic areas: organization of care networks; awareness of red flags; use of innovative diagnostic tools; evaluation of the value of early diagnosis; integration of the patient's perspective; implementation of multidisciplinary teams. The results highlight the need to standardize organizational models based on Hub-and-Spoke networks, strengthen the role of the territory in the early identification of suspected cases, and integrate emerging technologies, including artificial intelligence and biomarkers, into diagnostic pathways. In addition, the importance of early diagnosis as an investment capable of generating long-term clinical and economic value is emphasized. The adoption of a holistic, patient-centered approach that includes quality of life and the active involvement of patients and caregivers is also central.

Il progetto AMY-Way: potenziare il percorso diagnostico ed espandere la capacità assistenziale nella gestione dell’amiloidosi da transtiretina in Italia. Una expert opinion multidisciplinare / Obici, L., Luigetti, M., Di Brino, E., Limongelli, G., Sinagra, G., D'Alessio, G.. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 0034-1193. - 117:11(2026), pp. 512-528. [10.1701/4802.48276]

Il progetto AMY-Way: potenziare il percorso diagnostico ed espandere la capacità assistenziale nella gestione dell’amiloidosi da transtiretina in Italia. Una expert opinion multidisciplinare

Sinagra, Gianfranco
Penultimo
;
2026-01-01

Abstract

Transthyretin (ATTR) amyloidosis is a rare, progressive, and multisystem disease, today recognized as underdiagnosed and characterized by significant diagnostic delays, which compromise timely access to effective disease-modifying therapies. In light of recent therapeutic innovations, early diagnosis and integrated management are key to improving clinical outcomes and patients' quality of life. The AMY-Way project was created to identify operational strategies to enhance the diagnostic and care pathways for ATTR amyloidosis in Italy through a multidisciplinary approach. A group of experts, using the mini-Delphi methodology, developed six priority thematic areas: organization of care networks; awareness of red flags; use of innovative diagnostic tools; evaluation of the value of early diagnosis; integration of the patient's perspective; implementation of multidisciplinary teams. The results highlight the need to standardize organizational models based on Hub-and-Spoke networks, strengthen the role of the territory in the early identification of suspected cases, and integrate emerging technologies, including artificial intelligence and biomarkers, into diagnostic pathways. In addition, the importance of early diagnosis as an investment capable of generating long-term clinical and economic value is emphasized. The adoption of a holistic, patient-centered approach that includes quality of life and the active involvement of patients and caregivers is also central.
File in questo prodotto:
File Dimensione Formato  
06_Expert opinion - Obici.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 752.27 kB
Formato Adobe PDF
752.27 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/3151422
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact